AbbVie confirms FDA grants full approval for Elahere for certain ovarian cancers

AbbVie announced that the U.S. Food and Drug Administration has granted full approval for , mirvetuximab soravtansine-gynx, for the treatment of folate receptor alpha-positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal adult cancer patients treated with up to three prior therapies. Patients with these cancers often present with late-stage disease, undergo surgery and are then treated with platinum-based chemotherapy. They may become resistant to this treatment and require another therapy, such as Elahere. “The full FDA approval of Elahere for eligible patients with ovarian cancer represents the culmination of years of work by the ImmunoGen team. Elahere is the first and only antibody-drug conjugate, or ADC, approved in the U.S. for this difficult-to-treat malignancy,” said Roopal Thakkar, M.D., senior vice president, chief medical officer, global therapeutics, AbbVie.